Raymond James Financial
SNDX icon

Raymond James Financial’s Syndax Pharmaceuticals SNDX Stock Holding History

Raymond James Financial’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$323K Buy
13,841
+2,714
+24% +$59K ﹤0.01% 4618
2025
Q4 		$234K Buy
11,127
+158
+1% +$2.76K ﹤0.01% 4715
2025
Q3 		$169K Hold
10,969
– – ﹤0.01% 4662
2025
Q2 		$103K Buy
+10,969
New +$121K ﹤0.01% 4858

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Raymond James Financial's SNDX Position: Q1 2026 in Review

Raymond James Financial increased its Syndax Pharmaceuticals (SNDX) stake by 24% in Q1 2026, buying an estimated $59K and bringing the position to 13,841 shares worth $323K. The position accounts for ﹤0.01% of the portfolio, ranked #4618.

Raymond James Financial first reported a position in SNDX in Q2 2025 and has held it in 4 quarters since. 247 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Raymond James Financial held 13,841 shares of Syndax Pharmaceuticals worth $323K as of Q1 2026.
  • Raymond James Financial bought 2,714 Syndax Pharmaceuticals shares in Q1 2026, an estimated $59K.
  • Syndax Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #4618 holding.
  • Raymond James Financial first reported a position in Syndax Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 247 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.